Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
Hong Kong · Delayed Price · Currency is HKD 5.78
-0.28 (-4.54%)
Sep 11, 2026, 4:08 PM HKT
HKG:1167 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 738.73 | 53.53 | 155.71 | 63.52 | 95.75 | 152.81 | |
Revenue Growth | 266.85% | -65.63% | 145.13% | -33.66% | -37.34% | -68.58% |
Cost of Revenue | 18.76 | 0.59 | - | 60.32 | 83.11 | 139.98 |
Gross Profit | 719.98 | 52.93 | 155.71 | 3.2 | 12.63 | 12.83 |
Selling, General & Admin | 34.52 | 34.43 | 43.05 | 46.62 | 42.55 | 44.58 |
Research & Development | 187.54 | 188.59 | 330.18 | 372.32 | 445.65 | 280.84 |
Other Operating Expenses | -21.64 | -3.84 | -14.33 | -3.78 | 5.36 | -20.27 |
Operating Expenses | 200.42 | 219.17 | 358.89 | 415.16 | 493.56 | 305.14 |
Operating Income | 519.55 | -166.24 | -203.19 | -411.95 | -480.93 | -292.31 |
Interest Expense | -11.01 | -12.94 | -8.4 | -8.31 | -2.27 | -0.57 |
Interest & Investment Income | 33.71 | 31.7 | 40.86 | 47.07 | 24.61 | 18.77 |
Earnings From Equity Investments | -1.34 | -0.53 | - | - | - | - |
Currency Exchange Gain (Loss) | -45.47 | -16.24 | 12.19 | 20.69 | 82.53 | -27.26 |
EBT Excluding Unusual Items | 495.44 | -164.25 | -158.53 | -352.51 | -376.05 | -301.38 |
Gain (Loss) on Sale of Investments | -0.93 | -0.9 | -0.02 | -7.24 | 4.19 | 0.19 |
Gain (Loss) on Sale of Assets | 19.14 | 19.17 | -0.14 | 0.63 | - | - |
Other Unusual Items | - | - | 2.98 | - | - | - |
Pretax Income | 513.66 | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 |
Earnings From Continuing Operations | 513.64 | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 |
Net Income | 513.64 | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 |
Net Income to Common | 513.64 | -145.98 | -155.71 | -359.12 | -371.86 | -301.19 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 774 | 775 | 775 | 773 | 752 | 747 |
Shares Outstanding (Diluted) | 777 | 775 | 775 | 773 | 752 | 747 |
Shares Change | 0.43% | -0.04% | 0.26% | 2.79% | 0.61% | 96.13% |
EPS (Basic) | 0.66 | -0.19 | -0.20 | -0.46 | -0.49 | -0.40 |
EPS (Diluted) | 0.66 | -0.19 | -0.20 | -0.46 | -0.49 | -0.40 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -212.15 | -86.21 | -402.03 | -308.86 | -157.6 |
Free Cash Flow Per Share | - | -0.27 | -0.11 | -0.52 | -0.41 | -0.21 |
Gross Margin | 97.46% | 98.89% | 100.00% | 5.04% | 13.20% | 8.40% |
Operating Margin | 70.33% | -310.59% | -130.49% | -648.54% | -502.29% | -191.29% |
Profit Margin | 69.53% | -272.73% | -100.00% | -565.36% | -388.38% | -197.10% |
Free Cash Flow Margin | - | -396.35% | -55.37% | -632.92% | -322.58% | -103.13% |
EBITDA | 526.93 | -153.68 | -190.69 | -401.12 | -473.71 | -285.57 |
EBITDA Margin | 71.33% | -287.12% | -122.47% | - | - | -186.88% |
D&A For EBITDA | 7.37 | 12.56 | 12.49 | 10.83 | 7.21 | 6.74 |
EBIT | 519.55 | -166.24 | -203.19 | -411.95 | -480.93 | -292.31 |
EBIT Margin | 70.33% | - | -130.49% | - | - | -191.29% |